Skip to main content
SpringerLink
Log in

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide

  • Short Communication
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either lumbar spinal bone mineral density or T-score. Furthermore, serum sclerostin was increased after 6 months treatment with risedronate, whereas remained unchanged after 6 months teriparatide treatment.

Introduction

The primary aim of this study was the evaluation of serum sclerostin levels in postmenopausal women and their association with bone mineral density (BMD) and bone turnover markers. The secondary aim was the evaluation of treatment with either teriparatide (TPTD) or risedronate (RIS) on serum sclerostin levels in women with postmenopausal osteoporosis.

Methods

Women with postmenopausal osteoporosis, assigned to receive either TPTD (TPTD group, n = 13) or RIS (RIS group, n = 36) for 6 months, and non-osteoporotic early postmenopausal women (NOEP group, n = 13) were recruited. Main outcome measure was serum sclerostin levels.

Results

Serum sclerostin was higher in the NOEP group at baseline compared with either TPTD group (p = 0.007) or RIS group (p = 0.049). Sclerostin was positively correlated with both lumbar spinal (LS) BMD (r = 0.353; p = 0.005) and T-score (r = 0.501; p < 0.001) and negatively correlated with intact parathyroid hormone (r = −0.343; p = 0.024) at baseline. Multiple regression analysis showed that either LS BMD (Beta = 0.653; p = 0.018) or T-score (Beta = 0.711; p = 0.005) were independent predictors of serum sclerostin levels. No significant correlation was observed between serum sclerostin and bone turnover markers or estradiol at baseline. Sclerostin was significantly increased 6 months post-treatment in RIS group (p = 0.002), whereas remained statistically unaffected in the TPTD group.

Conclusions

Serum sclerostin is decreased in women with postmenopausal osteoporosis compared with non-osteoporotic early postmenopausal women and is positively correlated to either LS BMD or LS T-score. Furthermore, serum sclerostin was increased after 6 months treatment with RIS, whereas remained essentially unchanged after 6 months TPTD treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99–107

    Article  PubMed  CAS  Google Scholar 

  2. Trivedi R, Mithal A, Chattopadhyay N (2010) Anabolics in osteoporosis: the emerging therapeutic tool. Curr Mol Med 10:14–28

    Article  PubMed  CAS  Google Scholar 

  3. Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543

    Article  PubMed  CAS  Google Scholar 

  4. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844

    PubMed  CAS  Google Scholar 

  5. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887

    Article  PubMed  CAS  Google Scholar 

  6. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417:664–667

    Article  PubMed  CAS  Google Scholar 

  7. Lewiecki EM (2009) Emerging drugs for postmenopausal osteoporosis. Expert Opin Emerg Drugs 14:129–144

    Article  PubMed  CAS  Google Scholar 

  8. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47:529–533

    Article  PubMed  CAS  Google Scholar 

  9. Padhi D, Jang G, Stouch B, Fang L, Posvar E (2010) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. doi:10.1002/jbmr.173

    Google Scholar 

  10. Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A (2008) Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract 62:919–924

    Article  PubMed  CAS  Google Scholar 

  11. Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A (2008) Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res 40:281–285

    Article  PubMed  CAS  Google Scholar 

  12. Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E (2010) The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol Oxf 72:752–757

    Article  PubMed  CAS  Google Scholar 

  13. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Lawrence RB, Joseph ML III, Khosla S (2010) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. doi:10.1002/jbmr.217

    Google Scholar 

  14. Melton LJ III, Looker AC, Shepherd JA, O’Connor MK, Achenbach SJ, Riggs BL, Khosla S (2005) Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int 16:1558–1564

    Article  PubMed  Google Scholar 

  15. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056–5062

    Article  PubMed  CAS  Google Scholar 

  16. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997

    Article  PubMed  Google Scholar 

  17. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248–2253

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 13 Simou Lianidi, 551 34, Thessaloniki, Greece

    S. A. Polyzos

  2. Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece

    A. D. Anastasilakis

  3. Biomarker Design Forschungs GmbH, Vienna, Austria

    C. Bratengeier

  4. Biomedica Medizinprodukte GmbH & Co KG, Vienna, Austria

    W. Woloszczuk

  5. Department of Medical Research, 251 General Airforce Hospital, Athens, Greece

    A. Papatheodorou

  6. Department of Clinical Therapeutics, School of Medicine, University of Athens, Athens, Greece

    E. Terpos

Authors
  1. S. A. Polyzos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. D. Anastasilakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Bratengeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Woloszczuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Papatheodorou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Terpos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. A. Polyzos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polyzos, S.A., Anastasilakis, A.D., Bratengeier, C. et al. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide. Osteoporos Int 23, 1171–1176 (2012). https://doi.org/10.1007/s00198-010-1525-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-010-1525-6

Keywords

Search

Navigation